Navigation Links
Off-Label Avastin Use for Wet Macular Degeneration
Date:2/25/2008

Treatment Could Save Millions Their Sight

PORTLAND, Ore., Feb. 25 /PRNewswire/ -- The Food and Drug Administration (FDA) has only approved Avastin for cancer of the colon and lungs. In off-label use, however, Avastin is proving itself as a "miracle drug" that's currently used by some doctors to treat other cancers, including breast, prostate, renal cell, head and neck, pancreatic, ovarian and hepatocellular.

Some ophthalmologists are also turning to Avastin for wet age-related macular degeneration (AMD), the leading cause of blindness in people over 50 years old. Wet AMD is a growing concern for aging adults. There are 200,000 new cases of the disease every year and experts project the number will increase rapidly as baby boomers age and their life expectancy increases. Experts estimate 6.3 million people will lose their vision to wet AMD by 2030. They also predict the disease will cost half a million people their sight each year.

In wet AMD, abnormal blood vessels grow at the back of the eye and leak blood and fluids into the macula, the central part of the retina. Like a high-definition digital camera, the eye's macula picks up fine-grained pictures so you can see their detail. Untreated wet AMD rapidly causes rapid vision loss and without the macula you cannot read fine print, recognize faces or drive.

"Because wet AMD is a devastating disease that progresses swiftly, ophthalmologists want to treat it immediately," explains Dr. Skip Freedman, executive medical director at AllMed Healthcare Management, a leading independent review organization (IRO). "And there is strong medical evidence that Avastin and Luncentis are the most effective treatment for wet AMD today."

According to Freedman, both drugs bind and inactivate the growth of blood vessels in the macula. In 2006, the FDA approved Genentech's Luncentis for wet AMD. However, because Genentech researchers derived both Luncentis and Avastin from the same monoclonal antibody, a substance that can find and bind to cancer cells anywhere in the body, some ophthalmologists began using Avastin. At about $2,000 a dose for Luncentis and about $50 for Avastin, they saw them as an equal, but Avastin as a more cost-effective treatment.

Genentech claims it is concerned about public safety and believes that compounding Avastin might increase the risk of eye infections during treatment. The company also says that because Avastin is a much larger protein, it may not be as efficacious as Lucentis. However, ophthalmologists currently have reported no contamination issues or increased eye infections using Avastin instead of Lucentis. The National Eye Institute is conducting a study comparing the safety and efficacy of Avastin and Lucentis. However, Genentech declined taking part in it, saying it is unnecessary and potentially too costly. Early results of this comparison are expected to be available in 2009.

Today ophthalmologists consider Avastin and Lucentis equivalent treatments. Both are superior to others available and are the standard of care for wet AMD. Most states have started coverage for Avastin injections into the eye. Nationally, the use of Avastin instead of Lucentis to treat wet AMD could potentially save several billion dollars a year.

"Healthcare insurers need to consider working with independent review organizations to decide the right balance of treatment cost versus efficacy," said Dr. Freedman. "The case of whether ophthalmologists should use Avastin or Lucentis to treat wet AMD is just one example of how medical knowledge about drugs is changing more rapidly than health insurers can keep up. To contain healthcare costs, insurers must consider the medical necessity of a drug, as well as the lowest possible treatment cost for both its on- and off-label use to deliver patients cost-effective treatments that work."

For more information on leading-edge treatments and their medical necessity check out http://www.allmedmd.com/peerpoints/cuttingedge/cutting_edge_email.htm. To find out more about the review services IROs offer go to AllMed's Website at http://www.allmedmd.com.


'/>"/>
SOURCE AllMed Healthcare Management
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Study looks at off-label use of biliary stents
2. FDA Panel Says No to Avastin for Advanced Breast Cancer
3. Taxol with avastin produces noteworthy results
4. Many More Patients Can Now Benefit from Avastins Proven Survival Benefits
5. Despite Oncologists Willingness to Prescribe Avastin for Treatment of Breast Cancer, the FDA is Likely to Rule Against the Product on February 23
6. In Combination With FOLFOX4, the Effect of Erbitux and Avastin On Survival Rates Will Drive Prescription Decisions in the Treatment of Stage III Colon Cancer
7. FDA OKs Avastin for Advanced Breast Cancer
8. $37 million financing for company based on macular degeneration research
9. Model to study age-related macular degeneration could pave way for better treatment
10. Optherion Licenses Worldwide Rights to Develop Age-Related Macular Degeneration Diagnostics Based on Chromosome 10 Genetic Variations
11. Neurotech Announces Completion of Enrollment of its Phase II/III Retinitis Pigmentosa and Phase II Dry Age Related Macular Degeneration Clinical Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2016)... ... ... a year and a half of planning the Multiple Pathways of Recovery Conference , ... Recovery Conference was held May 2 -4, 2016 at the Mystic Marriott Hotel & ... explore the many pathways individuals use to get into and sustain their recovery. Pathways ...
(Date:5/27/2016)... ... 2016 , ... More than a third of American adults are considered obese, ... has received increased attention in recent years, as an article published May ... loss, most people are familiar with the basic requirements of maintaining a healthy diet ...
(Date:5/27/2016)... ... May 27, 2016 , ... Two director-level employees of Horizon Blue Cross ... and Industry (TWIN) 2016 honorees. The award recognizes businesswomen who excel in their ... Boone, Director of the MLTSS (Managed Long-Term Services and Supports) Program at Horizon NJ ...
(Date:5/27/2016)... ... 27, 2016 , ... An influential resource amongst nurses and professionals in the ... on the variety of topics detailing why we appreciate nurses in so many different ... has gone from being in a major recession to one of the hottest growing ...
(Date:5/27/2016)... York, NY (PRWEB) , ... May 27, 2016 , ... ... factors of a stroke, which we as a society can control and change. , ... stroke occurs nearly every 40 seconds within the United States. Plus, with an estimated ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... , May 25, 2016 ... H1 2016"market research report that provides an overview ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ... also reviews key players involved in the therapeutic ...
(Date:5/24/2016)... AMSTERDAM , May 24, 2016 ... aplicación médica para ayudar a los médicos a compartir ... los pacientes a escala mundial. Profesionales médicos de Europa, ... ya se han apuntado a la aplicación, que combina ... en un entorno totalmente seguro. Educación   ...
(Date:5/24/2016)...   , Study met both ... superiority in , Excellent plus Good ... of the ascending colon   , ... today announced new positive data from the phase III MORA study ... 2 litre PEG with ascorbate. The study met both primary endpoints ...
Breaking Medicine Technology: